The association between these three oncogenes may highlight the activation of several signaling pathways associated to tyrosine kinase receptors, suggesting the use of TKI combinations could be a suitable therapeutic strategy and would explain better response rates observed in NSCLC patients with WSE [8, 24]. Here, NTRK1 is linked to non-small cell lung carcinoma.